SCHEMBL14947685

SCHEMBL14947685

Cc1n[nH]cc1-c1ccnc(S(C)(=O)=O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 5/20 0.41
PARP1 P09874 1/20 0.35
CDK2 P24941 2/20 0.34
DYRK1A Q13627 2/20 0.33
DYRK2 Q92630 1/20 0.33
SDHB P21912 2/20 0.32
AURKA O14965 1/20 0.31
MAP4K4 O95819 1/20 0.31
ABL1 P00519 1/20 0.31
LCK P06239 1/20 0.31
MET P08581 1/20 0.31
PDGFRB P09619 1/20 0.31
FGFR1 P11362 1/20 0.31
FLT1 P17948 1/20 0.31
KDR P35968 1/20 0.31
FLT3 P36888 1/20 0.31
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460112 0.82 DYRK1B (0.34) DYRK1BPARP1CDK2DYRK1ADYRK2
SCHEMBL3575717 0.77 BPTF (0.43) DYRK1BSDHBAURKAMAP4K4ABL1
SCHEMBL5090972 0.75 JAK3 (0.37) DYRK1BKDRBRAFEGFRCYP3A4
SCHEMBL3250098 0.75 MAPT (0.39) DYRK1BCDK2DYRK1AMAP4K4LCK
SCHEMBL14947686 0.73 CCNA2 (0.51) PARP1CDK2DYRK1ADYRK2CDK9
SCHEMBL14947687 0.72 CCNE1 (0.47) DYRK1BCDK2DYRK1ADYRK2FGFR1
SCHEMBL3917534 0.72 CYP3A4 (0.39) PDGFRBLRRK2BRAFEGFRCYP3A4
SCHEMBL3909205 0.72 CYP3A4 (0.39) DYRK1BDYRK1APDGFRBCLK4BRAF
SCHEMBL31443295 0.72 MAPK8 (0.52) DYRK1BDYRK1ADYRK2AURKAMET
SCHEMBL3568782 0.72 CDK2 (0.59) CDK2AURKACDK9AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123281-A1 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules BETA CAT PHARMACEUTICALS, LLC (US) 2013-05-16 US disclosed
US-20130123281-A1 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules BETA CAT PHARMACEUTICALS, LLC (US) 2013-05-16 US disclosed
WO-2013071232-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF TBL-1 BINDING TO DISEASE-ASSOCIATED MOLECULES BETA CAT PHARMACEUTICALS, LLC (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123281-A1 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules TBL2, TBL3, TBL1XR1 DYRK1B 3499/4885PARP1 4098/4885CDK2 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.